{"entity":{"id":"nct06631989","kind":"trial","name":"A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of WSD0922-FU in non-small-cell lung cancer, run by Wayshine Biopharm, Inc., now recruiting.","summary":"A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06631989 by Wayshine Biopharm, Inc., with 100 participants planned, started 2024-09-04 and due to reach its primary completion in 2027-06-30. Interventions recorded: WSD0922-FU.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06631989","url":"https://clinicaltrials.gov/study/NCT06631989"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06631989","phase":"1/2","setting":"A Phase I/II Multicenter, Open Label, Single-arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of WSD0922-FU in the Treatment of Advanced Non-small Cell Lung Cancer","sponsor":"Wayshine Biopharm, Inc.","enrolled":100,"outcomes":[]},"route":"/trials/nct06631989/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}